

United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO	
APPLICATION NO.	FILING DATE		50623.26	3752	
09/748,412	12/21/2000	Wouter E. Roorda	50025120		
			EXAM	EXAMINER	
7590 04/07/2004			PHAN, HIEU		
Souire, Sande	rs & Dempsey L.L.P.		,		
Suite 300			ART UNIT	PAPER NUMBER	
One Maritime Plaza San Francisco, CA 94111			3738		
Jan I Ianoisco,			DATE MAILED: 04/07/2004		

Please find below and/or attached an Office communication concerning this application or proceeding.

	Application No.	Applicant(s)				
-	09/748,412	ROORDA, WOUTER E.				
Office Action Summary	Examiner	Art Unit				
	Hieu Phan	3738				
The MAILING DATE of this communication app Period for Reply	ears on the cover sheet with the	correspondence address				
A SHORTENED STATUTORY PERIOD FOR REPLY THE MAILING DATE OF THIS COMMUNICATION. - Extensions of time may be available under the provisions of 37 CFR 1.13 after SIX (6) MONTHS from the mailing date of this communication. - If the period for reply specified above is less than thirty (30) days, a reply of NO period for reply is specified above, the maximum statutory period was a reply reply received by the Office later than three months after the mailing earned patent term adjustment. See 37 CFR 1.704(b).	36(a). In no event, however, may a reply be ti within the statutory minimum of thirty (30) da rill apply and will expire SIX (6) MONTHS fron cause the application to become ABANDON	mely filed ys will be considered timely. the mailing date of this communication. ED (35 U.S.C. § 133).				
Status						
1) Responsive to communication(s) filed on 18 De	ecember 2003.					
2a)⊠ This action is FINAL . 2b)☐ This	This action is FINAL . 2b) ☐ This action is non-final.					
closed in accordance with the practice under E	x parte Quayle, 1935 C.D. 11, 4	53 O.G. 213.				
Disposition of Claims						
4)⊠ Claim(s) <u>1-4,8,10,12-14 and 16-23</u> is/are pending in the application.						
4a) Of the above claim(s) 8,13,14,16,17 and 21-23 is/are withdrawn from consideration.						
5) Claim(s) is/are allowed.						
6)⊠ Claim(s) <u>1-4,10,12 and 18-20</u> is/are rejected.						
7) Claim(s) is/are objected to.						
8) Claim(s) are subject to restriction and/or	election requirement.					
Application Papers						
9) The specification is objected to by the Examiner	•					
10) The drawing(s) filed on is/are: a) accepted or b) objected to by the Examiner.						
Applicant may not request that any objection to the o	frawing(s) be held in abeyance. Se	e 37 CFR 1.85(a).				
Replacement drawing sheet(s) including the correcti	on is required if the drawing(s) is ob	ejected to. See 37 CFR 1.121(d).				
11)☐ The oath or declaration is objected to by the Ex	aminer. Note the attached Office	Action or form PTO-152.				
Priority under 35 U.S.C. § 119						
12) Acknowledgment is made of a claim for foreign a) All b) Some * c) None of: 1. Certified copies of the priority documents 2. Certified copies of the priority documents 3. Copies of the certified copies of the priority application from the International Bureau * See the attached detailed Office action for a list of	have been received. have been received in Applicatity documents have been received (PCT Rule 17.2(a)).	ion No ed in this National Stage				
* See the attached detailed Office action for a list of	or the certified copies not receive	su.				
Attachment(s)						
1) Notice of References Cited (PTO-892)	4) Interview Summary					
2)	Paper No(s)/Mail D 5) Notice of Informal F 6) Other:	ate Patent Application (PTO-152)				

Application/Control Number: 09/748,412

Art Unit: 3738

Response to Amendment

Applicant's request for reconsideration of the finality of the rejection of the last
 Office action is persuasive and, therefore, the finality of that action is withdrawn.

Drawings

2. The drawings are objected to under 37 CFR 1.83(a). The drawings must show every feature of the invention specified in the claims. Therefore, the device and the coating containing the first and second region must be shown or the feature(s) canceled from the claim(s). No new matter should be entered.

A proposed drawing correction or corrected drawings are required in reply to the Office action to avoid abandonment of the application. The objection to the drawings will not be held in abeyance.

3. The drawings are objected to under 37 CFR 1.83(a). The drawings must show every feature of the invention specified in the claims. Therefore, the "stent" and a "coating containing a first region... and a second region" must be shown or the feature(s) canceled from the claim(s). No new matter should be entered.

A proposed drawing correction or corrected drawings are required in reply to the Office action to avoid abandonment of the application. The objection to the drawings will not be held in abeyance.

4. Examiner require applicant to provide a drawings because it would help to better understand the claimed invention during the prosecution of the application.

Application/Control Number: 09/748,412

Art Unit: 3738

Claim Rejections - 35 USC § 102

5. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless -

- (b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.
- 6. Claims 1-4, 10, 12 and 18-20 are rejected under 35 U.S.C. 102(b) as being anticipated by Fearnot et al. (U.S. Patent 5,609,629).

Fearnot et al. disclosed a porous stent (10) having second region (18) with component for reducing infiltration of macrophages (column 8 lines 46-67, column 9 lines 1-26) and first region (20 and or 24) with component for reducing or preventing the formation of thrombi (column 12 lines 39-41, Abstract, column 2 lines 66 and 67, column 3 lines 1-16 and 30-67, column 4 lines 23-39 and 48-61, column 5 lines 12-47 and column 7 lines 5-22 and 30-47).

Response to Arguments

7. Applicant's arguments filed 12/18/2003 have been fully considered but they are not persuasive. In regard to claims 1, 10, 18 and 19, Fearnot et al. clearly disclose in figure 2 having a stent (10) with first region (20) with a component for reducing or preventing the formation of thrombi (column 12 lines 28-41) and a second region (18) with a component for reducing or preventing infiltration of macrophages (column 8 lines 46-67 and column 9 lines 1-21). Therefore the rejection under 35 U.S.C. 102(b) as being anticipated by Fearnot et al. (U.S. Patent 5,609,629) is proper.

Application/Control Number: 09/748,412

Art Unit: 3738

8. Please note, Fearnot et al. was use to reject the current application as a 35 U.S.C. 102(b) rejection instead of a 35 U.S.C. 103(e) rejection because upon further inspection of the prior art, Examiner came to the conclusion that that Fearnot et al. read on all the limitations of the claimed invention (refer to paragraphs 5-7).

Conclusion

9. **THIS ACTION IS MADE FINAL.** Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action.

10. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Hieu Phan whose telephone number is 703-308-8969. The examiner can normally be reached on Monday-Friday from 8am-5pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Corrine M McDermott can be reached on 703-308-2111. The fax phone number for the organization where this application or proceeding is assigned is 703-872-9306.

Art Unit: 3738

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Hieu Phan Examiner Art Unit 3738

CORRINE MCDERMOTT

SUPERVISORY
TECHNOLOGY CENTER 3700